Neuropsychiatric Adverse Reactions to Mefloquine: a Systematic Comparison of Prescribing and Patient Safety Guidance in the US, UK, Ireland, Australia, New Zealand, and Canada

@inproceedings{Nevin2016NeuropsychiatricAR,
  title={Neuropsychiatric Adverse Reactions to Mefloquine: a Systematic Comparison of Prescribing and Patient Safety Guidance in the US, UK, Ireland, Australia, New Zealand, and Canada},
  author={Remington Lee Nevin and Aricia M. Byrd},
  booktitle={Neurology and therapy},
  year={2016}
}
INTRODUCTION The antimalarial drug mefloquine (MQ) is associated with neuropsychiatric adverse reactions, some of which may predict the development of more serious effects. Although prescribing guidance in the United States drug label (DL) recommends to discontinue MQ at the onset of neuropsychiatric symptoms, only certain reactions are listed in both the DL and the corresponding patient medication guide with a recommendation to discontinue or to consult a physician should they occur. To… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 55 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Roche

  • F. Hoffman-L
  • U.S. Lariam dear health care professional letter…
  • 2003
Highly Influential
3 Excerpts

and Drug Administration

  • U. S. Foo
  • FDA drug safety communication: FDA approves label…
  • 2016
1 Excerpt

Similar Papers

Loading similar papers…